Flavivirus vaccines.
Diseases caused by flavivirus infection have been a scourge of mankind for over three centuries; with yellow fever, dengue fever and Russian spring-summer encephalitis causing epidemics resulting in thousands of fatalities. Due to the development of a safe and efficacious live-attenuated vaccine against yellow fever, this disease is no longer such a threat in countries where adequate vaccination is practised. A similarly safe and efficacious inactivated vaccine against central-European tick-borne encephalitis has also been developed and this has drastically reduced the incidence of this disease in many countries where it is endemic. In spite of these successes, the development of vaccines against other pathogenic flaviviruses, causing diseases such as dengue fever and Russian spring-summer encephalitis, have not been successful. This review attempts to summarize the development of flavivirus vaccines to date and identify areas for future improvements. Problems associated with designing flavivirus vaccines are discussed and the advantages and disadvantages of future strategies for vaccine development are considered.
Stephenson
J R
JR
Division of Biologics, Centre for Applied Microbiology and Research, Porton Down, Salisbury, UK.
D000914:Antibodies, Viral / Q000276:immunology; D000918:Antibody Specificity; D004665:Encephalitis Virus, St. Louis; D004669:Encephalitis Viruses, Tick-Borne; D005416:Flavivirus / Q000276:immunology*; D006481:Hemorrhagic Fever, Omsk; D006801:Humans; D014611:Vaccination; D014765:Viral Vaccines; D014779:Virus Replication; D015005:Yellow fever virus
D000914:Antibodies, Viral; D014765:Viral Vaccines